The GlioFocus study is an international Phase 3 clinical trial for adults who have been newly diagnosed with glioblastoma that is MGMT‑unmethylated, a type of tumour that does not respond well to standard chemotherapy. The study is comparing a newer targeted cancer drug, niraparib, with the usual chemotherapy drug temozolomide, and both treatments are given alongside standard radiotherapy

Participants are randomly assigned to receive either niraparib plus radiotherapy or temozolomide plus radiotherapy. After the radiotherapy stage—which lasts about six to seven weeks—patients continue with the same study medication: niraparib is taken for as long as the cancer remains stable, while temozolomide continues for up to six additional cycles.

The study aims to find out whether niraparib can keep the cancer under control for longer and improve survival compared with temozolomide, as earlier research suggested niraparib may reach tumour tissue more effectively and may help extend life when combined with radiotherapy.

Around 450 patients will take part globally, and each participant may be involved in the study for several years, including long‑term follow‑up of up to five years after treatment to monitor their health and the longer‑term effects of therapy